HBM Holdings Limited (HKG:2142)

Revenue by Product

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Molecule License Fee - Upfront Payment	165.32M
Molecule License Fee - Milstone Payment	66.89M
Research Service Fee	54.24M
Research Service Fee Growth	118.62%
Technology License Fee	10.85M
Technology License Fee Growth	82.05%

Revenue by Geography

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Europe	152.52M
Europe Growth	6907.60%
United States	78.01M
United States Growth	-87.29%
China	59.69M
China Growth	-28.06%
Other	7.07M
Other Growth	360.71%